Physician profile
Frank D Wright
NPI 1376525618
$1,957.92
in general payments reported to CMS, 2019-2025
27 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $54.97 · 2021: $483 · 2022: $167 · 2023: $468 · 2024: $224 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $939.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $293.95 | 2021-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $244.51 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $184.30 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $165.88 | 2022-2025 | Ubrelvy, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.21 | 2019-2022 | |
| Heidelberg Engineering, INC. | $105.63 | 2021 | |
| Valeritas, INC. | $88.51 | 2019 | |
| Novartis Pharmaceuticals Corporation | $75.40 | 2019-2023 | |
| Amarin Pharma, INC. | $72.13 | 2019-2020 | |
| Pfizer INC. | $64.26 | 2019-2023 | |
| Exact Sciences Corporation | $61.71 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $49.19 | 2024 | Otezla, Repatha, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.12 | 2023-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $43.77 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.19 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $40.37 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $39.01 | 2021 | |
| Janssen Pharmaceuticals, INC | $34.64 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $33.83 | 2019-2023 | Breztri |
| Abbott Laboratories | $31.18 | 2021 | |
| Merck Sharp & Dohme LLC | $24.73 | 2020-2021 | |
| Acclarent, INC | $22.28 | 2019 | |
| Nevro Corp. | $21.79 | 2024 | Senza |
| Biogen, INC. | $20.44 | 2025 | Leqembi |
| Idorsia Pharmaceuticals US INC | $19.53 | 2023 | Quviviq |
| Aprecia Pharmaceuticals, LLC | $13.43 | 2023 | Spritam |
| Otsuka America Pharmaceutical, INC. | $12.93 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.